Peptide And Oligonucleotide CDMO Market Size, Share & Trends Report

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report by Services, by End User, by Region, And Segment Forecasts, 2023 To 2030

Report ID: GVR454141
Number of Pages: 0
Format: Electronic (PDF)

Historical Data: ---
Industry: Healthcare

Table of Content

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
  1.1.2. Product
  1.1.3. End User
  1.1.4. Regional scope
  1.1.5. Estimates and forecast timeline
  1.2. Research Methodology
  1.3. Information Procurement
  1.3.1. Purchased database
  1.3.2. GVR’s internal database
  1.3.3. Secondary sources
  1.3.4. Primary research
  1.4. Information or Data Analysis
  1.4.1. Data analysis models
  1.5. Market Formulation & Validation
  1.6. Model Details
  1.6.1. Commodity flow analysis (Model 1)
  1.6.2. Volume price analysis (Model 2)
  1.7. List of Secondary Sources
  1.8. List of Primary Sources
  1.9. Objectives
  1.9.1. Objective 1
  1.9.2. Objective 2
  1.9.3. Objective 3
  1.9.4. Objective 4
Chapter 2. Executive Summary
  2.1. Market Outlook
Chapter 3. Peptide and Oligonucleotide CDMO Market Variables, Trends & Scope
  3.1. Market Lineage Outlook
  3.1.1. Parent market outlook
  3.1.2. Related/ancillary market outlook
  3.2. Market Dynamics
  3.2.1. Market driver analysis
  3.2.2. Market restraint analysis
  3.2.3. Covid-19 Impact & Recovery Analysis
  3.2.4. Industry Analysis - Porter’s
  3.2.5. PESTLE Analysis
Chapter 4. Peptide and Oligonucleotide CDMO Market: Phase Segment Analysis
  4.1. Peptide and oligonucleotide CDMO market Market : Definition & Scope
  4.2. Peptide and oligonucleotide CDMO market Market : Phase Market Share Analysis, 2022 & 2030
  4.2.1. Discovery
4.2.1.1. Discovery Market, 2018 - 2030 (USD Million)
  4.2.2. Pre-Clinical
  4.2.2.1. Pre-Clinical Market, 2018 - 2030 (USD Million)
  4.2.3. Clinical
  4.2.3.1. Clinical Market, 2018 - 2030 (USD Million)
Chapter 5. Peptide and Oligonucleotide CDMO Market: Product Segment Analysis
  5.1. Peptide and oligonucleotide CDMO market Market : Definition & Scope
  5.2. Peptide and oligonucleotide CDMO market Market : Product Market Share Analysis, 2022 & 2030
  5.2.1. API
  5.2.1.1. APIMarket, 2018 - 2030 (USD Million)
  5.2.2. Drug Product
  5.2.2.1. Drug Product Market, 2018 - 2030 (USD Million)
  5.2.3. Others
  5.2.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Peptide and Oligonucleotide CDMO Market: End User Segment Analysis
  6.1. Peptide and oligonucleotide CDMO market Market : Definition & Scope
  6.2. Peptide and oligonucleotide CDMO market Market : End User Market Share Analysis, 2022 & 2030
  6.2.1. Pharmaceutical Companies
  6.2.1.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
  6.2.2. Biotech Companies
  6.2.2.1. Biotech Companies Market, 2018 - 2030 (USD Million)
  6.2.3. Others
  6.2.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Analysis
  7.1. Peptide and Oligonucleotide CDMO Market: Regional market share analysis, 2022 & 2030
  7.2. North America
  7.2.1. North America Market estimates and forecast, 2018 - 2030
  7.2.2. U.S.
  7.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
  7.2.3. Canada
  7.2.3.1. Canada Market estimates and forecast, 2018 - 2030
  7.3. Europe
  7.3.1. Europe Market estimates and forecast, 2018 - 2030
  7.3.2. UK
  7.3.2.1. UK Market estimates and forecast, 2018 - 2030
  7.3.3. Germany
  7.3.3.1. Germany Market estimates and forecast, 2018 - 2030
  7.3.4. France
  7.3.4.1. France Market estimates and forecast, 2018 - 2030
  7.3.5. Italy
  7.3.5.1. Italy Market estimates and forecast, 2018 - 2030
  7.3.6. Spain
  7.3.6.1. Spain Market estimates and forecast, 2018 - 2030
  7.3.7. Denmark
  7.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
  7.3.8. Sweden
  7.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
  7.3.9. Norway
  7.3.9.1. Norway Market estimates and forecast, 2018 - 2030
  7.4. Asia Pacific
  7.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
  7.4.2. Japan
  7.4.2.1. Japan Market estimates and forecast, 2018 - 2030
  7.4.3. China
  7.4.3.1. China Market estimates and forecast, 2018 - 2030
  7.4.4. India
  7.4.4.1. India Market estimates and forecast, 2018 - 2030
  7.4.5. South Korea
  7.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
  7.4.6. Australia
  7.4.6.1. Australia Market estimates and forecast, 2018 - 2030
  7.4.7. Thailand
  7.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
  7.5. Latin America
  7.5.1. Latin America Market estimates and forecast, 2018 - 2030
  7.5.2. Brazil
  7.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
  7.5.3. Mexico
  7.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
  7.5.4. Argentina
  7.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
  7.6. MEA
  7.6.1. MEA Market estimates and forecast, 2018 - 2030
  7.6.2. South Africa
  7.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
  7.6.3. Saudi Arabia
  7.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
  7.6.4. UAE
  7.6.4.1. UAE Market estimates and forecast, 2018 - 2030
  7.6.5. Kuwait
  7.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030
Chapter 8. Competitive Landscape
  8.1. Company Profiles
  8.1.1. WuXi STA
  8.1.1.1. Company overview
  8.1.1.2. Financial performance
  8.1.1.3. Service benchmarking
  8.1.1.4. Strategic initiatives
  8.1.2. Bachem
  8.1.2.1. Company overview
  8.1.2.2. Financial performance
  8.1.2.3. Service benchmarking
  8.1.2.4. Strategic initiatives
  8.1.3. Creative Peptides
  8.1.3.1. Company overview
  8.1.3.2. Financial performance
  8.1.3.3. Service benchmarking
  8.1.3.4. Strategic initiatives
  8.1.4. Aurigene Pharmaceutical Services Ltd.
  8.1.4.1. Company overview
  8.1.4.2. Financial performance
  8.1.4.3. Service benchmarking
  8.1.4.4. Strategic initiatives
  8.1.5. Merck KGaA
  8.1.5.1. Company overview
  8.1.5.2. Financial performance
  8.1.5.3. Service benchmarking
  8.1.5.4. Strategic initiatives
  8.1.6. Curia Global, Inc.
  8.1.6.1. Company overview
  8.1.6.2. Financial performance
  8.1.6.3. Service benchmarking
  8.1.6.4. Strategic initiatives
  8.1.7. CordenPharm
  8.1.7.1. Company overview
  8.1.7.2. Financial performance
  8.1.7.3. Service benchmarking
  8.1.7.4. Strategic initiatives
  8.1.8. Polypetide Group
  8.1.8.1. Company overview
  8.1.8.2. Financial performance
  8.1.8.3. Service benchmarking
  8.1.8.4. Strategic initiatives
  8.1.9. ST Pharm Co.Ltd.
  8.1.9.1. Company overview
  8.1.9.2. Financial performance
  8.1.9.3. Service benchmarking
  8.1.9.4. Strategic initiatives
  8.1.10. Sylentis, S.A.
  8.1.10.1. Company overview
  8.1.10.2. Financial performance
  8.1.10.3. Service benchmarking
  8.1.10.4. Strategic initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.